Rallybio hits high gear as it targets $100M IPO to fund treatments for rare fetal bleeding disorder

Rallybio ended the first quarter with nearly $128 million in the bank, and it’s heading to Wall Street for more. The company filed Friday to raise up to $100 million in its IPO, which will advance a pair of treatments for a rare fetal bleeding disorder through phase 1 as well as get programs for complement disorders into the clinic.